Literature DB >> 31593833

Association of arginine vasopressin (AVP) promoter polymorphisms with preeclampsia.

Saiedeh Erfanian1, Leila Yazdanpour2, Danesh Javeshghani3, Abazar Roustazadeh4.   

Abstract

OBJECTIVES: Preeclampsia (PE) is a disease of pregnancy characterized by early onset of maternal hypertension and proteinuria. New findings indicate that arginine vasopressin (AVP) may be a contributing factor to ignite PE. The aim of this study was to identify if there is any correlation between arginine vasopressin promoter polymorphisms and PE. STUDY
DESIGN: Venous blood samples of 100 PE and 100 normal pregnant women were obtained for DNA extraction to identify the polymorphisms of AVP promoter by RFLP and nested-PCR techniques. MAIN OUTCOME: rs3729965 polymorphism of PE women was detected to have significant correlation with body mass index (BMI) (P = 0.028).
RESULTS: Statistical analysis of three polymorphisms namely rs3729965, rs61138008 and rs3761249 of preeclamptic women (PEW) and none preeclamptic pregnant women (NPEW) revealed that rs3729965 genotypic distribution was significantly different between both groups (P = 0.04). Further analysis revealed that rs3729965 CT genotype of PEW had significant correlation to their BMI (P = 0.028).
CONCLUSION: Polymorphic variants located on the promoter region of AVP are associated with PE. Thus we hypothesize that allelic variation may have a role in increasing the risk of developing PE.
Copyright © 2019 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Arginine vasopressin; Polymorphism; Preeclampsia

Mesh:

Substances:

Year:  2019        PMID: 31593833     DOI: 10.1016/j.preghy.2019.09.017

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  1 in total

1.  Copeptin in Patients with Pregnancy-Induced Hypertension.

Authors:  Agnieszka Marek; Rafał Stojko; Agnieszka Drosdzol-Cop
Journal:  Int J Environ Res Public Health       Date:  2021-06-15       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.